Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 46

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 46
---
 by Enfusion as a result of the Enfusion Board determining to enter into a definitive agreement with respect to a Superior Proposal (as defined
in the section titled “The Merger Agreement—No Solicitation of Other Offers by Enfusion”) or (c) a termination (i) by Clearwater or Enfusion as a result of the Closing not occurring prior to the End Date, (ii) by either
Clearwater or Enfusion because the Stockholder Approval has not been obtained at the Special Meeting, or (iii) by Clearwater because of a breach of any representation or warranty or failure to perform any covenant or agreement on the part of
Enfusion; provided that, in the case of clauses (c)(i), (ii) and (iii), Enfusion will pay the termination fee only if (x) after the date of the Merger Agreement and prior to the termination of the Merger Agreement, a bona fide
Acquisition Proposal (as defined below) is publicly disclosed and not irrevocably withdrawn at least three business days prior to the Special Meeting and (y) within 12 months after the date of such termination, Enfusion enters into any
Acquisition Proposal or consummates any Acquisition Proposal (provided that for purposes of this determination, each reference to “20% or more” or “80% or less” in the definition of Acquisition Proposal will be deemed to
be references to “more than 50%” or “less than 50%,” respectively).

All other expenses relating to the transactions
will generally be paid by the party incurring the expense.

Specific Performance; Remedies(see page 144)

In addition to any other remedy that may be available to each party, including monetary damages, each of the parties will be entitled to an
injunction or injunctions or equitable relief to prevent breaches of the Merger Agreement and to enforce specifically its terms and provisions.

Comparison of Rights of Common Stockholders of Clearwater and Enfusion(see page 164)

Enfusion Stockholders receiving shares of Clearwater Common Stock in connection with the Transactions will have different rights once they
become holders of Clearwater Common Stock (“”) due to differences between the governing corporate documents of Clearwater and Enfusion. These differences are described in more detail in the section titled
“Comparison of Stockholder Rights.”

TRA Amendment(see page 112 andAnnex C)

In connection with Enfusion’s initial public offering in October 2021, Enfusion entered into a tax receivable agreement, dated